UNITED THERAPEUTICS Corp Insider Trading Activity
Every SEC Form 4 insider transaction reported for UNITED THERAPEUTICS Corp (UTHR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are UTHR insiders buying or selling?
In the last 12 months, UNITED THERAPEUTICS Corp insiders reported 0 open-market purchases ($0) and 287 sales ($1.4B) — net selling of $1.4B. Since March 2018, Trabud has recorded 701 Form 4 filings for UTHR: 1 buys ($529.16) and 700 sells ($2.4B).
Source: SEC EDGAR Form 4
What stands out
- No UNITED THERAPEUTICS Corp insider made an open-market purchase in the last 12 months; the 287 reported open-market sales totaled $1.4B.
Key Statistics (March 2018 – Oct 16, 2026)
Total Form 4 filings
701
SEC EDGAR
Insider filers
15
Insider buys (1)
$529.16
Insider sells (700)
$2.4B
Insider sentiment
Net sellingNet insider flow of $2.4B in net selling since March 2018, and $1.4B in net selling over the last 12 months.
Recent UTHR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $546.65 | $5.2M | SEC ↗ |
| Oct 16, 2026 | Paul A Mahon | EVP & GENERAL COUNSEL | Sale | 8.3K | $544.30 | $4.5M | SEC ↗ |
| Oct 15, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $539.99 | $5.1M | SEC ↗ |
| Oct 14, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $545.52 | $5.2M | SEC ↗ |
| Oct 13, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $550.70 | $5.2M | SEC ↗ |
| Oct 13, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $544.94 | $5.2M | SEC ↗ |
| Oct 9, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $534.31 | $5.1M | SEC ↗ |
| Oct 8, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $548.95 | $5.2M | SEC ↗ |
| Oct 7, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $538.67 | $5.1M | SEC ↗ |
| Oct 6, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $541.64 | $5.1M | SEC ↗ |
| Oct 5, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $549.37 | $5.2M | SEC ↗ |
| Oct 2, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $576.47 | $5.5M | SEC ↗ |
| Oct 1, 2026 | Paul A Mahon | EVP & GENERAL COUNSEL | Sale | 8.3K | $564.95 | $4.7M | SEC ↗ |
| Oct 1, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 1.9K | $550.22 | $1.1M | SEC ↗ |
| Oct 1, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 7.6K | $517.97 | $3.9M | SEC ↗ |
| Sep 30, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $477.42 | $4.5M | SEC ↗ |
| Sep 29, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $480.85 | $4.6M | SEC ↗ |
| Sep 28, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $476.17 | $4.5M | SEC ↗ |
| Sep 25, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $473.55 | $4.5M | SEC ↗ |
| Sep 24, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $491.57 | $4.7M | SEC ↗ |
| Sep 23, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $494.83 | $4.7M | SEC ↗ |
| Sep 22, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $494.55 | $4.7M | SEC ↗ |
| Sep 21, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $494.79 | $4.7M | SEC ↗ |
| Sep 18, 2026 | Martine A Rothblatt | Chairperson & CEO | Sale | 9.5K | $496.06 | $4.7M | SEC ↗ |
| Sep 18, 2026 | Paul A Mahon | EVP & GENERAL COUNSEL | Sale | 8.3K | $497.54 | $4.1M | SEC ↗ |
Showing the 25 most recent of 701 Form 4 filings for UNITED THERAPEUTICS Corp.
Most active UTHR insiders
- Martine A Rothblatt375 filings
- Paul A Mahon104 filings
- James Edgemond49 filings
- Michael Benkowitz48 filings
- Christopher Causey24 filings
Ask anything about UTHR insider activity
Use Trabud's AI agent to query UNITED THERAPEUTICS Corp's Form 4 history in plain English — "Show me UTHR CEO purchases this year" or compare it against any other ticker.
Open the AI agentUTHR insider trading FAQ
Are UNITED THERAPEUTICS Corp insiders buying or selling?
In the last 12 months, UNITED THERAPEUTICS Corp insiders reported 0 open-market purchases ($0) and 287 sales ($1.4B) — net selling of $1.4B. Since March 2018, Trabud has recorded 701 Form 4 filings for UTHR: 1 buys ($529.16) and 700 sells ($2.4B). Over the full record that is net selling of $2.4B.
How many insiders trade UTHR stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for UNITED THERAPEUTICS Corp. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get UTHR insider trading data?
All UTHR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.